STAT

Key study of Grail’s cancer detection test fails in setback for company

A blood test for detecting cancer early being developed by the diagnostics firm Grail failed to meet its main goal in a giant ...

Grail Says Multi-Cancer Screening Test Failed to Meet Trial's Primary Endpoint

Grail said Galleri, its multi-cancer early detection test, failed to meet the primary endpoint of a recent trial. The stock slid 47%, to $54.20, in after-hours trading. Through market close, share ...
Stocktwits on MSN

GRAL stock slumps after hours as trial for cancer test fails to show reduction in late-stage diagnoses

GRAIL, however, highlighted a favorable trend toward fewer Stage III-IV cancers in a pre-specified group of 12 deadly cancers ...

Wisconsin lawmakers pass Gail’s Law to expand breast cancer screening access, heads to Evers’ desk

Wisconsin lawmakers have overwhelmingly passed a bipartisan bill, 96-0, that would significantly expand access to breast ...